Differential prognosis of single and multiple TP53 abnormalities in high count MBL and untreated CLL

Overview of attention for article published in Blood Advances, July 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news: 9 news outlets

twitter: 5 X users

Readers on

mendeley: 20 Mendeley

So far, Altmetric has seen 9 news stories from 9 outlets.

February 27th 2025

CURE, 27 Feb 2025

By Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd and Dany Habr, M.D. Nathan, who is living with CLL, and his family…

BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL

Crwe World, 04 Dec 2024

About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test…

BeiGene and CLL Society Partner to Advance Test Before Treat(TM) Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL

Stockwatch, 04 Dec 2024

About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test…

BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL

ADFN, 04 Dec 2024

About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 5 additional news stories.